✨ Medicines Consents




22 NOVEMBER 2012 NEW ZEALAND GAZETTE, No. 139 4047

Medicines Act 1981

Renewal of Provisional Consent to the Distribution of Medicines

Pursuant to section 23(4A) of the Medicines Act 1981, the Minister of Health hereby renews the provisional consent to the sale, supply or use in New Zealand of the medicines set out in the Schedule hereto:

Schedule

Product: Noradrenaline Tartrate
Active Ingredient: Noradrenaline acid tartrate monohydrate 0.12g/L equivalent to Noradrenaline base 0.06g/L
Dosage Form: Solution for infusion
New Zealand Sponsor: Biomed Limited
Manufacturer: Biomed Limited, Auckland, New Zealand
Note: This renewed consent is valid for two years from 2 December 2012.

Product: Noradrenaline Tartrate
Active Ingredient: Noradrenaline acid tartrate monohydrate 0.159g/L equivalent to Noradrenaline base 0.08g/L
Dosage Form: Solution for infusion
New Zealand Sponsor: Biomed Limited
Manufacturer: Biomed Limited, Auckland, New Zealand
Note: This renewed consent is valid for two years from 2 December 2012.

Product: Noradrenaline Tartrate
Active Ingredient: Noradrenaline acid tartrate monohydrate 0.199g/L equivalent to Noradrenaline base 0.1g/L
Dosage Form: Solution for infusion
New Zealand Sponsor: Biomed Limited
Manufacturer: Biomed Limited, Auckland, New Zealand
Note: This renewed consent is valid for two years from 2 December 2012.

Product: Noradrenaline Tartrate
Active Ingredient: Noradrenaline acid tartrate monohydrate 0.239g/L equivalent to Noradrenaline base 0.12g/L
Dosage Form: Solution for infusion
New Zealand Sponsor: Biomed Limited
Manufacturer: Biomed Limited, Auckland, New Zealand
Note: This renewed consent is valid for two years from 2 December 2012.

Product: Noradrenaline Tartrate
Active Ingredient: Noradrenaline acid tartrate monohydrate 0.319g/L equivalent to Noradrenaline base 0.16g/L
Dosage Form: Solution for infusion
New Zealand Sponsor: Biomed Limited
Manufacturer: Biomed Limited, Auckland, New Zealand
Note: This renewed consent is valid for two years from 2 December 2012.

Dated this 15th day of November 2012.

DR PAT TUOHY, Acting Chief Medical Officer, Clinical Leadership, Protection and Regulation Business Unit, Ministry of Health (pursuant to delegation given by the Minister of Health on 6 July 2001).

go7553

Consent to the Distribution of New Medicines

Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines set out in the Schedule hereto:

Schedule

Product: Apo-Perindopril
Active Ingredient: Perindopril erbumine 2mg
Dosage Form: Tablet
New Zealand Sponsor: Apotex NZ Limited
Manufacturers: Apotex Inc, Ontario, Canada
Apotex Research Private Limited, Bangalore, India

Product: Apo-Perindopril
Active Ingredient: Perindopril erbumine 4mg
Dosage Form: Tablet
New Zealand Sponsor: Apotex NZ Limited
Manufacturers: Apotex Inc, Ontario, Canada
Apotex Research Private Limited, Bangalore, India



Next Page →



Online Sources for this page:

Gazette.govt.nz PDF NZ Gazette 2012, No 139





✨ LLM interpretation of page content

πŸ₯ Renewal of Provisional Consent to the Distribution of Medicines

πŸ₯ Health & Social Welfare
15 November 2012
Medicines Act 1981, Provisional Consent, Noradrenaline Tartrate, Biomed Limited, Auckland
  • Dr Pat Tuohy, Acting Chief Medical Officer, Clinical Leadership, Protection and Regulation Business Unit, Ministry of Health

πŸ₯ Consent to the Distribution of New Medicines

πŸ₯ Health & Social Welfare
Medicines Act 1981, New Medicines, Apo-Perindopril, Apotex NZ Limited, Apotex Inc, Apotex Research Private Limited